NovAccess Global Advisory on Annual Meeting of Shareholders
NovAccess Global Advisory on Annual Meeting of Shareholders
CLEVELAND, OH / ACCESSWIRE / May 7, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the postponement of its Annual Meeting of Shareholder which was previously scheduled to be held in May 2024. The Company expects to reschedule the annual meeting shortly.
俄亥俄州克利夫蘭/ACCESSWIRE/2024年5月7日/爲腦腫瘤患者開發新型免疫療法的生物醫學公司NovAccess Global Inc.（OTCQB: XSNX）今天宣佈推遲原定於2024年5月舉行的年度股東大會。該公司預計不久將重新安排年會。
The Company previously announced that it would be hosting a virtual annual meeting of shareholders on May 6th, 2024 for shareholders of record as of April 1, 2024.
該公司此前曾宣佈，將於5月6日舉辦虛擬年度股東大會第四，截至2024年4月1日登記在冊的股東爲2024年。
About NovAccess Global
關於 NovAccess
NovAccess Global is a biomedical company accelerating novel cancer diagnostics and therapeutics. Our goal is to discover, develop and bring to market novel and innovative medicine and medical devices to improve the quality of care for cancer and neurological patients.
NovAccess Global是一家加速新型癌症診斷和治療的生物醫學公司。我們的目標是發現、開發新穎和創新的藥物和醫療器械並將其推向市場，以提高癌症和神經系統患者的護理質量。
Follow us on social media and stay up to date on all of our developments:
在社交媒體上關注我們，隨時了解我們的所有最新動態：
Forward-Looking Statement
前瞻性陳述
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in the Company's disclosures or filings with the Securities Exchange Commission. You are further cautioned that penny stocks and stocks of smaller companies like NovAccess Global Inc. are inherently volatile and risky and that no investor should buy this stock unless they can afford the loss of their entire investment. The Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date thereof.
本新聞稿包含經修訂的1933年《證券法》第27A條和經修訂的1934年《證券交易法》第21E條所指的 “前瞻性陳述”，此類前瞻性陳述是根據1995年《私人證券訴訟改革法》的安全港條款作出的。“前瞻性陳述” 描述未來的預期、計劃、結果或策略，前面通常以 “可能”、“未來”、“計劃” 或 “計劃”、“將” 或 “應該”、“預期”、“預期”、“草稿”、“最終” 或 “預測” 等詞語開頭。請注意，此類陳述存在多種風險和不確定性，可能導致未來的情況、事件或結果與前瞻性陳述中的預測存在重大差異，包括由於各種因素，實際業績可能與前瞻性陳述中的預測存在重大差異的風險，以及公司向證券交易委員會披露或文件中確定的其他風險。進一步提醒您，細價股和像NovAccess Global Inc.這樣的小型公司的股票本質上是波動性和風險性的，除非投資者能夠承受全部投資的損失，否則任何投資者都不應購買該股票。公司不承擔任何更新任何前瞻性陳述以反映其後的事件或情況的義務。
Investor Relations Contact:
投資者關係聯繫人：
Jordan Darrow
Darrow Associates
631-766-4528
jdarrow@darrowir.com
喬丹·達羅
達羅合夥人
631-766-4528
jdarrow@darrowir.com
SOURCE: NovAccess Global Inc.
來源：NovAccess 全球公司
譯文內容由第三人軟體翻譯。